While clinical trial insurance is a necessity for any company that conducts clinical trials, many companies do not adequately fulfill their responsibilities when it comes to informed consent. Informed consent requires a deliberate process. This is not just a form that research coordinators push onto subjects.

Here, we’ll take an in-depth view of informed consent and how you can protect yourself by building a strong protocol for informed consent.

Go Beyond the Minimum Requirements

The Code of Federal Regulations does explicitly offer guidelines for informed consent, but the process of actually obtaining consent is not clear to many providers of clinical trials.

All subjects face a critical threshold when they are presented with informed consent forms. This is why clinical trials providers need to exercise great caution if they are working with a vulnerable segment of the population. Children, the elderly and mentally impaired people may not fully grasp the attributes of informed consent. As such, separate protocols should be established when obtaining their consent.

Here are the most traditional forms of finding participants for clinical trials:

The participant volunteered or took part in a recruitment program.
The participant is already part of a group of patients under study.
The clinical trial providers are offering the trial as a treatment option after informing the patient of the risks and benefits.

Encourage Participants to Ask Questions

While we clearly understand how patients learn about clinical trials, less is known about why certain people decide to participate. As a result, clear communication becomes very important in the clinical trial environment. Research coordinators should encourage participants to ask as many questions as possible. A structured communication plan will help protect providers from errors and omissions claims.

Organizations should attempt to make the informed consent document as short as possible. All participants should clearly understand the document, and it should be worded in layman’s terms, but should contain comprehensive information about the trial.

Clinical trial administrators should build rapport with patients, and should disclose all facts regarding the study. Clinical trial administrators should go over each segment of the informed consent document slowly and clearly, and should check with the subject to make sure they understand everything.

More and more studies are showing that participants are unaware of the risks and benefits of clinical trials. This further emphasizes the need for organizations to distinguish between what is research, and what is routine medical therapy.

HIPAA Regulations and Informed Consent

Clinical trial administrators also must clearly follow HIPAA regulations that pertain to clinical trials. HIPAA does require all participants to sign an authorization document  including all required information.

It’s obvious that all clinical trials providers are at risk for litigation. However, good life sciences insurance will cover the expenses incurred as a result of a lawsuit. Insurance professionals can also help advise sponsors and clinical research organizations regarding the informed consent process.

If you conduct clinical trials, be sure you establish a strong relationship with your insurance carrier. With a comprehensive clinical trial insurance policy, your company will be covered in the case of any litigation.

Perfect the CRO selection and management process – and guarantee trial success

Strategic Clinical Sourcing: Managing Costs and CROs aims to improve your company’s clinical outsourcing decision-making during every step of the process – from strategy setting to daily relationship management. Trial cost and timeline benchmarks – coupled with input from leading executives – will show trial teams how to efficiently and effectively manage outsourced trials.

Establish the tone for success with a proactive strategy
Trials will run into obstacles – it’s a fact. But attention to detail when assessing clinical needs and anticipating problems goes a long way toward desired outcomes. The report examines the groups and individuals who set strategy, the breakdown of tasks outsourced to vendors and the treatment of patient recruiting, a recurring challenge for trial teams.

Learn what other companies pay for outsourced trial activities
Clinical vendors’ expertise provides great opportunities for cost savings. Be confident in knowing that you are paying acceptable rates – benchmark against examples of trial budgets and unit hour costs for nine key roles. Also, data on peak-level headcounts for specific trial roles will help your company zero in on staffing needs.

Find the CRO best suited to your project and negotiate the contract
Clinical outcomes could ultimately bring lucrative results, so it’s important to choose a CRO wisely. Our study details a wide range of CRO traits and includes performance rankings of actual CROs. Beyond vendor selection, we reveal timeline data and strategies for improving the proposal review process.

Resolve conflicts quickly and ensure top-quality performance
Effectively managing trial progress, vendor relationships and development costs requires attention to both qualitative and quantitative performance indicators. Using data benchmarks and best practices, this chapter explores common complications that hinder trials, and it provides preventative solutions. Key topics include contract negotiation, vendor compensation, CRO performance and conflict resolution.

Sample Content from the Report

The following excerpt is taken from Chapter 1, “Clinical Outsourcing Strategy” section 1, “Evaluation of Core Clinical Development Capabilities.”

Outsourcing Strategy and Vendor Selection

A major difficulty faced by most teams is disagreement over vendor selection. From a strategic perspective, a CRO’s (or other vendor’s) size and reach factor directly into project plans. Different stakeholders will advocate niche- or full-service options, and the potential use of different vendors will impact decisions around specific activities. On a broader level, vendor ability to deliver satisfactory results for any given task will impact project management and outsourcing strategy.

Multifunctional involvement in the setting of outsourcing strategy ultimately aids vendor selection. Involving key stakeholders at an early point helps to align expectations, objectives and processes. In other words, as one sourcing executive put it, working across functions “gets everyone on the same page.” Different individuals and groups have the opportunity to share opinions on key tasks, in-house needs and vendor capabilities as the lead team determines what to outsource and to whom they should hand specific activities.

As the process continues, internal familiarity helps to defuse – or at least lessen – inevitable differences and keep outsourcing strategy focused. If stakeholders are used to working together, they are more likely to find common ground when called upon to make project decisions. To one degree or another, shared experience and strategic vision provide a working foundation for all stakeholders.

One strategic path that aids in this process, the use of preferred vendors, can deliver outstanding results – or leave clients with a project’s worth of unfulfilled promises. The best ongoing relationships position vendors as external arms of the clinical development group. Over time, they build deep knowledge of client objectives, processes and concerns. That information, combined with strong working relationships forged by constant contact in project after project, positions the vendor to best meet sponsor needs.

When the system works, it eliminates the need for a lengthy vendor-selection process. Better yet, the client knows what to expect and does not have to spend time training the vendor in internal minutiae.

For more information kindly visit

http://www.bharatbook.com/detail.asp?id=109618&rt=Strategic-Clinical-Sourcing-Managing-Costs-and-CROs.html

 

OR Contact us at

 

Bharat Book Bureau

207, Hermes Atrium, Sector 11, CBD Belapur, Navi Mumbai – 400 614, India.

Phone : +91 22 2757 8668 / 2757 9438

Fax : +91 22 2757 9131

E-mail : info@bharatbook.com

Website : www.bharatbook.com

Advances in Imaging Biomarkers: Innovative technologies, applications in R&D and clinical practice, and informatics and regulatory requirements

Imaging biomarkers, those quantified using imaging modalities including Magnetic Resonance Imaging and Positron Emission Tomography, are attractive for a variety of reasons: the methods of measurement used are non-invasive, and can provide information that cannot be obtained in other ways including a drug’s pharmacology and side effect profile, interaction of a drug and its target, delivery of a drug to its target, and the drug’s pharmacokinetic profile. In the clinical setting, imaging biomarkers can be used as a screening, diagnostic or prognostic tool as well as for monitoring treatment response.

Researchers have a vision that the introduction of imaging biomarkers will revolutionize basic research, drug development and treatment by providing non-invasive approaches that are translatable from the laboratory to the clinic and by allowing researchers and clinicians to see in great detail how drugs are behaving. The discovery and development of imaging biomarkers is an exciting and growing area and researchers across the globe are working to develop this vision.

The imaging technologies available today offer a variety of methods that can be used to quantify information and thus create useful biomarkers. Discovering the biomarker is perhaps the easy step, whilst the clinical follow up studies required to gain a better understanding of the utility of the biomarker are more complex, time consuming and expensive. This report discusses advances in key technologies, the use of imaging biomarkers in drug discovery and development and current use in clinical practice. It also outlines key collaborative initiatives in standardizing imaging technologies and informatics, improving quantification and qualification without which the vision will not be realized.

Key features of this report

• Highlight some of the key technologies for imaging biomarker development in different research or clinical settings, as well as pivotal technology developments.
• Analysis of the potential for using these technologies to improve drug discovery and clinical trials. The different organizational structures within pharmaceutical companies are discussed.
• Analysis of imaging biomarkers currently used in clinical practice as well as the future of imaging biomarkers in this setting.
• Case studies of individual imaging biomarkers and the companies or research collaborations responsible for their development.

Scope of this report

• Identify key technologies for development of imaging biomarkers to assist in biomarker discovery and development
• Identify the relevance of imaging biomarkers to drug discovery and development and the different organization structures being adopted by pharmaceutical companies to the implement them
• Learn about the important efforts of public-private consortia that are working to develop new imaging biomarkers, qualify existing imaging biomarkers and develop standards and clarify qualification processes
• Understand the potential for imaging biomarkers to improve diagnostic processes, enabling earlier disease identification and promoting preventive medicine
• Discover the potential of imaging biomarkers for improving decision making and terminating unsuitable drug projects at an early stage, as well as reducing costs in clinical care

Key Market Issues

• Improvements to the drug discovery and development process are needed urgently: Imaging biomarkers can be applied across the spectrum of drug discovery and development activities for validating targets, confirming mechanism of action, obtaining early indicators of bioactivity, assessing pharmacokinetic profiles, providing prognostic indicators and supporting regulatory filings and will help to improve decision making and success rates.
• Improved, non-invasive clinical diagnostic tools are required to help reduce the rising costs of health care: Currently around 95% of healthcare costs go towards treatment rather than prevention. However, if more money was spent on effective prevention the economic benefit could be considerable. Imaging biomarkers may provide diagnostic tools that identify diseases earlier in their pathology, enabling preventive measures to be taken.
• The development of imaging biomarkers relies on quantitative methods: whilst some imaging modalities are quantitative already, such as PET, others require specialist software or must be developed to incorporate quantification. Imaging technology developers are actively working in this field.
• The development, validation and qualification of imaging biomarkers is a large task: collaborative efforts that involve all stakeholders will be required if the full potential of imaging biomarkers in clinical medicine is to be realized.

Key findings from this report

• Imaging biomarkers are attractive: and are now widely used in drug discovery development and in clinical care. Imaging biomarkers provide non-invasive approaches that are translatable from the laboratory to the clinic and allow researchers and clinicians to see in great detail how drugs are behaving in vivo.
• Image quantification is improving: Nuclear imaging methods – PET and SPECT – are some of the most important to the field of imaging biomarkers because they have the required sensitivity and are potentially quantitative. The development of new molecular imaging probes is a growing and exciting area. MRI has limitations in terms of sensitivity as opposed to nuclear methods, although the methods are often non-proprietary and more MRI scanners are available in clinical practice. Sensitive contrast agents for MRI need to be very sophisticated. Future improvements in sensitivity, computer aided diagnostics and standardization will improve the potential for imaging biomarkers.
• Small animal imaging is a rapidly growing area in the preclinical development of new pharmaceuticals. Instrumentation to allow CT, PET, SPECT, MRI, ultrasound or optical imaging of small animals is available from a large number of suppliers and the largest pharma companies are actively developing their capabilities in this area. Some large pharma companies have also invested in dedicated clinical imaging centers, while others have chosen to outsource to specialist academic centers.
• In the clinical setting, MRI represents the most highly utilized technology and includes the diversity of methods available under the MRI banner, such as MRS, DCE-MRI, diffusion weighted MRI, fMRI and arterial spin labeling. The wide availability of MRI machines in hospital settings and imaging centers also makes this an attractive technique for biomarker detection. The use of nuclear imaging methods, such as PET and SPECT, is growing. This is catalyzed by the growing availability of targeted ligands that highlight particular pathways or metabolic events.

Key questions answered

• What has driven the increasing interest in imaging biomarkers in recent years?
• Which imaging modalities are at the forefront of the effort to develop and utilize imaging biomarkers for clinical practice now and in the future?
• To what extent can imaging biomarkers improve drug development? At which points should they be utilized and how?
• What is the role of public-private consortia in driving the discovery of methods and biomarkers? What is the membership of these consortia, what are their goals and how much have they achieved to date?
• What improvements in the provision of imaging services are required to enable the future use of imaging biomarkers? How does this differ in different locations?

For more information, please contact :

http://www.aarkstore.com/reports/Advances-in-Imaging-Biomarkers-Innovative-technologies-applications-in-R-D-and-clinical-practice-and-informatics-and-regulatory-requirements-46856.html

Contact : Minu
Aarkstore Enterprise
Tel : +912227453309
Mobile No: +919272852585
Email : contact@aarkstore.com

We would like to think that the research done by the pharmaceutical companies is honest, but more than one news story has shown otherwise. If we had the political will, or if the FDA was less political, drug trials could be made more honest almost immediately with one simple procedure. Unfortunately, that change has been fought by the drug companies. Let’s see why.

The English newspaper, The Guardian, recently reported on several systematic reviews of drug research. They clearly showed that pharmaceutical industry studies and clinical trials report positive results far more often than those funded independently (funded by those not selling the drugs tested). Is it just a coincidence that drug companies get more of the results that they’re looking for? No.

The drug companies probably almost never directly tamper with clinical drug trials, nor are they likely to change the reported results afterwards. Dishonesty or criminal behavior like that is probably very rare in drug research, because it isn’t needed. More subtle ways are available.

How To Manipulate Drug Research Results

The most common way to manipulate the results of drug research, is the simplest of all. If you want to show that a new pharmaceutical works, just get rid of the trials that show it doesn’t, and keep the ones that show some effect. Investigations have demonstrated that this is common, that negative data is often hidden or discarded.

Suppose a new drug is given to twelve groups of people who share a given disease. It appears to help the people in four of the groups, but the subjects in the other eight groups have no improvement or perhaps even get sicker or have serious side effects. Differing results from one trial to the next is common, since people get better or worse for many reasons. This is why many trials are necessary to be statistically significant.

What if in this case, the company decided that only the four trials with positive results are important, and they quietly get rid of the data from the other eight. Suddenly a drug with no real benefit appears to have helped in every clinical trial – at least every one we’ll know about. It is very bad science, of course, but one of the most common ways pharmaceutical companies manipulate drug research results.

How do we stop this? Researchers have been recommending an inexpensive solution to this problem for decades: make the companies register all trials, so none can be “lost.” To use the results of any drug research to get a new pharmaceutical approved, a company would have to register the trial before it begins, in a compulsory international trials registry. It would add very little to their costs.

Naturally the drug companies are against this simple idea, and certainly have their arguments to present. The most likely real reason they are fighting it is that it doesn’t allow them as much control over the “truth” or the results of drug research. And with our own FDA staffed by their friends and former coworkers, we can  expect this dishonesty to go on.

Scientists are concerned that industry interest in developing anti-infective drugs is waning and measures may be required to counter this trend.

They packed a Sept. 15 session here on “Why is big pharma getting out of anti-infective drug discovery?” at the 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy.

The number of submissions to the U.S. Food and Drug Administration in this area was down about 10% this year and “the quality of the compounds is somewhat less,” said Steven Projan, PhD, a vice president with Wyeth Research.

“The investment equation is shifting away from treating acute disease towards chronic disease, towards larger markets,” he said. As a result, many of the major pharmaceutical companies “have stopped or have greatly curtailed their anti-infective drug discovery work, especially for anti-bacterials.”

Other factors influencing the lack of anti-infective research are limited success in identifying novel agents and the difficulty and expense of conducting clinical trials, particularly if one is seeking an indication for treating drug-resistant infections.

Anti-infectives are the third largest segment of the pharmaceutical industry, with annual sales totaling billion.

Dawnrays is a Hong Kong-based pharmaceutical enterprise, supplying all kinds of pharmaceutical products. Welcome to visit our website to get more information.

Dawnrays has been devoting itself to the health of human beings. With the high sense of social responsibility, long business vision, and the continuous effort in technological innovations, Dawnrays continues to contribute to the society by producing low-cost high quality medicines in the market and achieve to become one of the best pharmaceutical companies worldwide.

Date : 19 October 2010
Venue : ITC Maratha, Mumbai, India

The pharmaceutical business is under huge pressure and needs to be more competitive if it is going to stay successful. Every day companies generate large amounts of data, much of which is never fully leveraged. Traditional approaches to data collection and management prevent the full curation of all data within a company, leading to a substantial opportunity lost for that company. Why is this? Do companies really understand the full power of the data they own? What can be done by your members of your organisation to advance the thinking and technology?

Download Brochure

India has developed into a super power for IT skills and has become a major hub for pharmaceutical and biotech manufacturing and contract research, the outsourcing business in various other segments is also exhibiting promise. Clinical trial data management and statistical analysis is one such area which is growing rapidly, accompanied by a variety of players entering into different models of this business. This conference will reflect on the data management business in India and review the emerging outsourcing models in this growing pharma industry.

Few tasks in R&D rival the complexity of clinical data management while its importance in providing clean and correctly mapped data carries direct impact on the success of drug submission. In times of increasing trial costs and the rising threat of clinical outsourcing, keeping ahead of competition and abreast of the latest developments is paramount to surviving a harsh CDM climate. The role of data managers has experienced a fundamental shift from doer to controller, from data collector to system administrator. This year’s conference will capture the essence of electronic data integration, interface interoperability and system optimisation to spearhead a global understanding of data standardisation and usher clinical data management into a time- and cost-efficient second generation. Meticulous care has been taken to offer practical solutions and real-life case studies to combat the challenges of CDM. Market leaders will share their ideas and outline their action plan to crucially assist your decision-making process when improving Data capture and integration, Outsourcing strategies, Data cleaning, validation and mapping, CDISC implementation and compliance, Vendor and project management skills

CDM 2010 will provide you with the data that you need to recognize this complex and rapidly-expanding sector. Knowing the future market, and what impact will that have on future business opportunities? This is your opportunity to stay ahead by learning the latest trends and networking with the trend setters.

It gives us immense pleasure in welcoming you to the Clinical Data Management ’2010.

Conference Agenda

Key Speakers

* Dinesh Pillaipakkamnatt, Global Head – DB Programming, IIS TS, Novartis
* Celestine Juliet, Project Manager, Regulatory Affairs, Clinical Research, Cipla
* Chirag Trivedi, Head – Medical Affaris Clinical Operations, Sanofi Aventis
* Poonam Sule, Senior Clinical Study Manager, Pfizer
* Anil Arekar, Senior Consultant – Biostatistics – Asia Pacific, Johnson & Johnson
* Deepti Sanghavi, Medical Advisor- Clinical Research, Wockhardt
* Milind Antani, Head-Pharma LifeSciences group, Nishith Desai Associates
* Zinobia Madan, Founder & Managing Director, ClinOma Healthcare
* Milind Sardesai, Medical & Regulatory Affairs, Clinical Research Physician, Chiltern
* Jino Joseph, Senior SAS Programmer, GlaxoSmithKline

KEY THEMES:-

* Current trends of clinical data management & how can you take advantage of the current global market
* Driving for success is highly vital, but are you driving as smart as with strategies and tips on the most efficient ways to register clinical trials and results while best utilizing available resources
* Data management, CMC SCM, operational requirements & CRO infrastructure in India & South Asia
* Discovering cutting edge EDC technology and assess the latest database and data capture systems available
* Leverage the importance of CDISC compliance and standardized data capture to achieve effortless submission
* Overview of the various types of data that data managers working in oncology handle and the associated challenges
* How to land up in finding the right BPO partner
* Achieving consistent application & implementation of data standards to speed trial process
* Identifying the key critical factors for developing knowledge and skills in vendor management
* Attain solid vendor management skills to expertly juggle outsourced tasks
* Discovering technologies and strategies for successful clinical data management
* Avoiding potential pitfalls of data management
* Working with limited budget to ensure on time study completion
* Be prepared for audits; site, CRO and in-process trial audits

WHO SHOULD ATTEND:-

The audience will be made up of Vice Presidents, Directors and Managers within pharmaceutical and biotech manufacturers from the following areas:

* Data Management
* Outsourcing
* Clinical Operations
* External Alliances
* Clinical Trials
* Clinical Research
* R&D
* Project Management
* Contracts
* Legal Counsel
* Data Management
* Clinical Operations
* Electronic Data Capture
* Clinical Trials
* Clinical IT
* Biostatistics
* E-Clinical Management
* Database Services
* Clinical Research
* Regulatory Affairs
* Quality Assurance

WHY SHOULD ATTEND:-

Clinical Data Management 2010 – “Creating an optimised data integration & standardised data collection for a secured future for CDM”

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the technology of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and technologies in the high-level conference.

To know more about this conference, please visit:
http://www.visionshopsters.com/conference-on-clinical-data-management-2010.php

Contact us:

Visionshopsters
Ph : 91-22-40583020
Email: info@visionshopsters.com
Website : www.visionshopsters.com

Manic Depressive Illness, also known as Bipolar Disorder, is not something that you experience once and then snap out of. It is with you all your life, can make your life an emotional roller coaster of hell, and is something you have to learn to live with.

As human beings, it’s normal for us to swing from happiness to sadness and back again depending on the circumstances. What separates this behavior from manic depressive illness is the intensity of the swings. It’s not unusual for the mood of a person with manic depressive illness to swing from giddy exhilaration to the deepest suicidal depression. It’s trying to control and live with those extremes that can make life very difficult for these people.

The symptoms of bipolar disorder usually arrive sometime in the late adolescent years. It can be extremely difficult to diagnose because it arrives at precisely the same time that hormonal and other factors are affecting them. Even normal teenagers’ emotions can swing wildly from one moment to the next.

The keys to living with manic depressive illness are to 1) get diagnosed early and 2) get proper treatment. Bipolar disorder, once diagnosed, is normally treated with a combination of mood stabilizers and therapy.

Mood stabilizers are psychiatric medications developed to stabilize the extreme mood shifts from mania and depression in those suffering from manic depression or bipolar disorder. Popular mood stabilizers are Lithium, Valproic acid, Lamotrigine, and Carbamazepine. A variety of mood stabilizers are constantly undergoing clinical trials in an attempt to find the best treatment possible for manic depression.

Before a medication can be advertised as being effective for a certain disease, it must be approved by the FDA. However, just because a medication does not have FDA approval does not mean that it is ineffective. It could simply be in trials or it could be that money is not available to do long term clinical trials. The best thing is to find a doctor or health provider that you trust and follow their recommendations.

Therapy, for many people, has an undeserved negative connotation. They feel that they’ll be stigmatized or viewed as crazy if they seek psychiatric help. But, for many people it can literally be a godsend.

Manic depression therapy treatment can be personalized or can take place in a group setting. Therapy can be very helpful in helping people understand themselves, understand their emotional swings, and understand that they have some control over this illness. Therapy can help them realize that they do not have to be an innocent bystander in their own life.

In the best cases, with the right treatment and medications, those suffering from bipolar disorder can manage to live an almost normal life. The more difficult cases may require hospital stays of various lengths to treat the problem.

Manic depression is an illness that affects millions of people. The best way to help those suffering from it is to bring it out of the closet and help them get the treatment that they need.

Global Biopharmaceutical Market Report (2010-2015)

The Global Biopharmaceutical Industry has come a long way since its first drug- Humulin was approved in 1982. Today more than three hundred biopharmaceuticals have already been approved and many more are in late stage clinical development. These drugs have not only advanced the prevention and treatment of a number of life threatening diseases, but have also provided the thrust for the continued success of the pharmaceutical industry. ( http://www.bharatbook.com/detail.asp?id=156981&rt=Global-Biopharmaceutical-Market-Report-2010-2015.html )

Under mounting economic pressures to increase their outputs, pharmaceutical manufacturers have embraced biopharmaceuticals as a means to maintain flow in their drying pipelines. Bringing a biopharmaceutical, however, represents a very risky proposition and out of every ten drugs that enter the clinical phases, only three manage to gain market approval. But the industry’s US$ 92 Billion figures and double digit growth rates in the last five years are a testimonial to the fact that the ones that finally do get approval represent goldmines for investors.

Although factors such as biosimilar entry and cost containment in the developed markets are likely to restrain the growth of this market in the coming years, Imarc expects that the high potency and ability of biopharmaceuticals to attack targets beyond the reach of traditional small molecule drugs gives the industry a huge scope for future growth. A rich late stage pipeline and the growth of emerging markets are also expected to be major drivers for growth in the next five years. It expects the global biopharmaceutical market to reach level of sales figures worth more than US$ 167 Billion by 2015.

New report “Global Biopharmaceutical Market Report (2010-2015)” gives a deep insight into the global biopharmaceutical market. The research study serves as an analytical as well as a statistical tool to understand the strengths, weaknesses, opportunities, threats, market trends, geographical structure, therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2015. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the global biopharmaceutical market in some form or the other.

For more information kindly visit : http://www.bharatbook.com/detail.asp?id=156981&rt=Global-Biopharmaceutical-Market-Report-2010-2015.html

Related Reports

World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies)
http://www.bharatbook.com/detail.asp?id=144576&rt=World-Pharmaceutical-and-Biopharmaceutical-Market-2010-2015-Pipeline-Analysis-of-the-Top-50-Companies.html

Global and China Biopharmaceutical Industry Report, 2010
http://www.bharatbook.com/detail.asp?id=154012&rt=Global-and-China-Biopharmaceutical-Industry-Report-2010.html

Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668 
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook

The commercial success of Rituxan in the treatment of NHL and Velcade and Revlimid in the treatment of MM has attracted the interest of pharmaceutical companies to these markets. There are 173 drugs in clinical development for these indications, the majority of which are molecular targeted therapies (MTTs). This contrasts with HL and MDS where there is limited pipeline activity.

Scope

* Examination of key pipeline candidates with in-depth clinical and commercial profiles of Phase III candidates
* Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2019 with product-specific assumptions

Highlights

There are currently 107 drugs in clinical development for NHL, of which 12 are in late phase development. This high R&D activity is due to the diverse nature of the diseases and the success of therapies such as Rituxan in these indications. Targeted therapies account for over half of drugs in development for NHL.

There are currently 15 drugs in clinical development for HL, of which 3 are in late phase development. Unmet needs persists in HL but are confined to relapsed patients and elderly patients, which are relatively small patient populations.

There are currently 66 drugs in clinical development for MM, of which 8 are in late phase development. MM is an incurable disease and there is a need for better and less toxic therapies across all lines of treatment.

Reasons to Purchase

* Segmentation and analysis of the current pipeline by developmental phase, drug class and company
* Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs